BRAF V600 E mutation-positive tumors
GPTKB entity
Statements (54)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:Oncology
|
| gptkbp:associated_with |
tumor microenvironment
inflammatory response immune evasion increased angiogenesis tumor markers increased risk of recurrence clinical features BRAF gene mutation |
| gptkbp:can_be |
aggressive
hormone-sensitive benign or malignant recurrent multifocal localized or systemic |
| gptkbp:can_be_used_to |
pain
heterogeneity differentiation specific symptoms metabolic changes cellular signaling alterations |
| gptkbp:can_detect |
gptkb:liquid
genetic testing |
| gptkbp:can_lead_to |
metastasis
secondary mutations |
| gptkbp:characterized_by |
V600 E amino acid substitution
|
| gptkbp:genetic_studies |
missense mutation
|
| https://www.w3.org/2000/01/rdf-schema#label |
BRAF V600 E mutation-positive tumors
|
| gptkbp:influences |
MAPK signaling pathway
|
| gptkbp:is_associated_with |
BRAF inhibitors
MEK inhibitors |
| gptkbp:is_common_in |
gptkb:Oncology
|
| gptkbp:is_found_in |
various tissues
|
| gptkbp:is_linked_to |
environmental factors
family history genetic predisposition poor prognosis |
| gptkbp:is_monitored_by |
imaging techniques
|
| gptkbp:is_often_seen_in |
younger patients
|
| gptkbp:is_recognized_by |
biopsy samples
|
| gptkbp:is_studied_in |
clinical trials
|
| gptkbp:may_have |
asymptomatic
|
| gptkbp:occurs_in |
multiple organs
|
| gptkbp:requires |
palliative care
multidisciplinary approach surgical intervention |
| gptkbp:resulted_in |
increased cell proliferation
resistance to certain therapies |
| gptkbp:treatment |
gptkb:immunotherapy
radiation therapy chemotherapy targeted therapy |
| gptkbp:bfsParent |
gptkb:dabrafenib
|
| gptkbp:bfsLayer |
6
|